# Pulmonology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Satchel Paige (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML047-SYN
- Date: 2026-07-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marcus Lindqvist-Bello, MD
- Calendar frame: modern shifted

- Requested by: Delphine Whitaker-Osei, MD

## Reason for consultation

Two years of breathlessness on exertion (mMRC 2) and a morning cough in a 73-year-old former smoker of about 30 pack-years, with a normal NT-proBNP and ECG. Please confirm or exclude COPD with spirometry interpreted with race-neutral equations, and advise on treatment, oxygen, rehabilitation and screening. **S**

## History

Mr. Paige, 73, a retired professional pitcher and former smoker of about 30 pack-years who stopped eleven years ago, is seen at the request of Dr. Whitaker-Osei for two years of breathlessness on exertion and a morning cough. He has had no exacerbations in the past year. Albuterol, started two weeks ago, helps before walks; he uses it once or twice a day. No chest pain, orthopnea or ankle swelling. He asked to see his results and how they are calculated. **S**

## Examination

| System | Finding |
|---|---|
| General | Tall, lean and alert; full sentences; oxygen saturation 94 percent on room air |
| Chest | Barrel-shaped; reduced breath sounds throughout with prolonged expiration; no wheeze or crackles |
| Cardiovascular | Regular rhythm; soft heart sounds; no raised jugular venous pressure or edema |
| Hands | No clubbing |

BP 132/80 mmHg; pulse 82 bpm; respirations 18/min; temperature 36.6 °C; oxygen saturation 94% on room air; weight 82.4 kg; BMI 22.6 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Whitaker-Osei's intake note and results: eosinophils 0.08 x 10^3/uL, alpha-1 antitrypsin 142 mg/dL, NT-proBNP 92 pg/mL, a normal ECG, hemoglobin 15.2 g/dL. Today: spirometry meeting ATS/ERS quality standards, FEV1 1.92 L before and 2.02 L after 400 micrograms of albuterol, FVC 3.48 L, post-bronchodilator FEV1/FVC 0.58, FEV1 61% of the GLI Global predicted value; room-air arterial blood gas pH 7.42, PaCO2 40 mm Hg, PaO2 70 mm Hg; six-minute walk 360 m with a lowest saturation of 90 percent; CAT 18, mMRC 2. FEV1 before bronchodilator: 1.92 L (low); FEV1 after bronchodilator: 2.02 L (low); FVC after bronchodilator: 3.48 L; FEV1/FVC after bronchodilator: 0.58 (low); FEV1 percent predicted after bronchodilator (GLI Global): 61% (low); Arterial pH: 7.42 [pH]; PaCO2: 40 mmHg; PaO2 (room air): 70 mmHg (low); Six-minute walk distance: 360 m (low). All results are synthetic.

## Assessment

1. **Diagnosis and severity** (J44.9). COPD is confirmed: the post-bronchodilator FEV1/FVC of 0.58 is below the GOLD fixed ratio of 0.70 and below the lower limit of normal, with only a small bronchodilator response. Following the 2023 ATS statement, the results were interpreted with the race-neutral GLI Global equations: FEV1 61% of predicted, GOLD grade 2 (moderate). Race-specific equations for African American men predict lower normal values and would have put his FEV1 near 70%, making his disease look milder than it is. The normal alpha-1 antitrypsin excludes deficiency. **S**
2. **Maintenance treatment** (J44.9). With a CAT of 18, mMRC 2 and no exacerbations in the past year he is in GOLD group B, for which GOLD 2025 recommends a LAMA with a LABA in one inhaler. An inhaled corticosteroid is not indicated: his eosinophils are 0.08 x 10^3/uL and he has had no exacerbations, so it would add the risk of pneumonia without benefit. A once-daily dry powder inhaler suits him; his inspiratory effort is strong, and he learned the technique on a placebo device. Treatment should be reviewed for symptoms and exacerbations at each visit; if exacerbations recur despite good technique, the eosinophil count guides the next step. **S**
3. **Oxygen** (J44.9). Pulse oximetry can overestimate arterial saturation in people with darker skin, so a room-air arterial blood gas was done. His PaO2 of 70 mm Hg is well above the long-term oxygen threshold of 55 mm Hg (60 with cor pulmonale or polycythemia), and his lowest walking saturation was 90 percent. Long-term oxygen did not help people with moderate desaturation in the LOTT trial, and he does not have the severe exertional hypoxemia for which the ATS suggests ambulatory oxygen. He needs no oxygen now; this will be reassessed if his saturations fall. **S**
4. **Rehabilitation and lung cancer screening** (J44.9). He is a good candidate for pulmonary rehabilitation (mMRC 2, CAT 18): twice a week for about ten weeks, with walk tests at entry and exit. He is eligible for lung cancer screening at 73 with about 30 pack-years, having quit eleven years ago, and is fit for treatment; after a shared decision he wants a low-dose CT. A CT may also show emphysema and coronary calcium, which would bear on his cardiovascular care. **S**
5. **Action plan and follow-up** (J44.9). A spoken and written action plan: the daily inhaler, the reliever, a same-day call for more breathlessness or a change in sputum color or amount, and 911 for breathlessness at rest, chest pain or confusion; influenza, RSV and COVID-19 vaccines in the autumn, PCV20 and Tdap already given; staying smoke-free. Spirometry yearly. Heart disease is common in COPD; the normal ECG and NT-proBNP are reassuring, and the statin is appropriate. **S**

## Recommendations

1. Umeclidinium 62.5 micrograms with vilanterol 25 micrograms, one inhalation each morning; albuterol as needed; no inhaled corticosteroid.
2. Check inhaler technique and adherence at every visit.
3. No long-term or ambulatory oxygen; reassess if resting saturation falls or he becomes more breathless.
4. Pulmonary rehabilitation twice a week for about ten weeks, with six-minute walks at entry and exit.
5. Low-dose CT for lung cancer screening now and yearly while eligible.
6. COPD action plan, spoken and written; autumn vaccines.
7. Spirometry in a year; report results with race-neutral equations.
8. Pulmonology review if he has two moderate exacerbations or a hospital stay, or if his saturations fall.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Whitaker-Osei, who saw him the same day. The spirometry results, the reference equations and the plan were explained to Mr. Paige with his own numbers; he asked whether the old way of scoring would have changed his care, and was told that it could have made his disease look milder than it is. The inhaler technique was taught and he demonstrated it correctly. **S**

## Follow-up

Dr. Whitaker-Osei continues his care at eight and fifteen weeks; pulmonology will see him again for repeated exacerbations, a hospital stay or falling oxygen levels. **S**

## Guideline basis

- Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025), Global Initiative for Chronic Obstructive Lung Disease
- Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement (2023), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine 2023;207(8):978-995)
- CMID: Clinical Monitoring Intelligence Database, COPD and hyperlipidemia monographs (2026), Aether Forge
- Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine 2023;208(4):e7-e26)
- Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine 2020;202(10):e121-e141)
- A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation (LOTT) (2016), Long-Term Oxygen Treatment Trial Research Group (New England Journal of Medicine 2016;375(17):1617-1627)
- Racial Bias in Pulse Oximetry Measurement (2020), Sjoding MW, et al. (New England Journal of Medicine 2020;383(25):2477-2478)
- Lung Cancer: Screening (2021), U.S. Preventive Services Task Force
